
	Three Months Ended				Nine Months Ended
(in thousands)	September 30, 2025		September 30, 2024		September 30, 2025		September 30, 2024
Revenue:
Screening revenue	$	32,807	$	25,374	$	96,319	$	77,076
Development services revenue	3,387		3,278		7,256		10,267
Total revenue	36,194		28,652		103,575		87,343
Costs and operating expenses:
Cost of screening revenue (exclusive of amortization of intangible assets) (1)(2)	15,910		15,970		52,379		45,481
Cost of development services revenue (1)(2)	544		1,442		2,216		3,499
Compensation	53,375		84,733		173,537		257,578
Depreciation and intangible assets amortization expense	37,646		38,630		112,577		114,808
Stock-based compensation	13,868		16,871		43,068		70,980
Professional services	8,831		11,298		27,353		52,459
Cloud computing and information technology	6,416		7,517		19,537		23,619
Clinical studies	7,835		8,048		20,020		39,280
Laboratory supplies and research collaborations	3,242		8,556		10,421		37,631
Facilities	5,517		6,185		16,510		21,344
Other segment expenses (3)	8,301		12,909		35,709		51,948
Goodwill and intangible assets impairment	—		—		28,000		1,420,936
Total costs and operating expenses	161,485		212,159		541,327		2,139,563
Loss from Operations	(125,291)		(183,507)		(437,752)		(2,052,220)
Other income (expense):
Interest income	6,107		11,661		20,695		17,367
Other income (expense), net	466		(561)		(929)		(514)
Benefit from income taxes	29,741		46,719		108,811		105,428
Net Loss	$	(88,977)	$	(125,688)	$	(309,175)	$	(1,929,939)

(2) Cost of screening revenue (exclusive of amortization of intangible assets) and cost of development services revenue include $1.3 million and $4.9 million of depreciation expense for the three and nine months ended September 30, 2025 and $0.6 million and $3.8 million for the three and nine months ended September 30, 2024.